Miftaraj, J
Tirzepatide, the active ingredient in Zepbound and Mounjaro, also targets GIP (glucose-dependent insulinotropic polypeptide) alongside GLP-1
The number of patients who discontinued taking tirzepatide also increased as the dosage increased, with patients taking 15 mg having a 25% discontinuation rate vs 5.1% for 5-mg patients and 11.1% for dulaglutide
[.] Depigmented lesions are more pronounced in individuals with darker skin tones, making facial and acral lesions particularly challenging to manage and often causing significant distress, anxiety, and low self-esteem in patients
Clinical trials started in January 2016 and ended in May 2017
Women are often told to simply bounce back after childbirth, with little medical acknowledgment of the biological shifts that affect metabolism, weight, mental health and overall health